A preclinical contract research organization (CRO) provides outsourced research services to pharmaceutical, biotechnology and medical device companies, as well as academic institutions, primarily during the early stages of drug discovery and development.
The preclinical CRO market consists of sales, by entities (organizations, sole traders and partnerships), of preclinical CRO services that are essential for evaluating the safety, efficacy, and pharmacokinetics of drug candidates prior to their progression to clinical trials. Preclinical CROs conduct critical testing to support drug development, ensuring that potential treatments meet necessary regulatory and scientific standards before advancing to human trials.
The global preclinical CRO market was valued at $3,755.82 million in 2018 which grew till 2023 at a compound annual growth rate (CAGR) of more than 6.0%.
Increased Focus On Personalized Medicine
Increased focus on personalized medicine propelled the growth of the preclinical CRO market in the historic period. Personalized medicine frequently requires intricate study designs, including the evaluation of multiple biomarkers or genetic variants. Preclinical CROs possess the expertise needed to manage these complex studies, providing specialized skills in designing and conducting experiments tailored to the specific needs of personalized treatment approaches. For instance, in October 2022, according to the Personalized Medicine Coalition, a US-based organization that represents scientists, patients and providers, promoting the understanding and adoption of personalized medicine to benefit patients and the healthcare system) estimated that more than 75,000 genetic testing products and 300 personalized medicines were on the market for people with multiple types of cancers, genetic rare diseases and a range of chronic and infectious diseases. Additionally, personalized medicines were estimated to account for 34% of new drug approvals by the US Food and Drug Administration in 2022 and have accounted for at least 25% of approvals in each of the previous eight years. Therefore, increased focus on personalized medicine supported the growth of the preclinical CRO market during the historic period.
Innovative CRO Solutions Combine Traditional Services With Cutting-Edge Technology
Companies in the preclinical CRO market are deploying innovative CRO solutions that combine traditional services with cutting-edge technology. This integration optimizes multiple facets of clinical trials, including planning, recruitment, data management and analysis. For instance, in June 2024, Lindus Health, a UK-based clinical research organization, launched an "All-in-One Medical Device CRO" that combines traditional CRO services with unique recruitment capabilities and proprietary eClinical technology. This new offering utilizes a database of over 30 million electronic health records (EHRs) and in-house digital marketing strategies for participant recruitment. It also provides extensive in-house site capabilities, including virtual and hybrid options, as well as a network of physical community sites.
The global preclinical CRO market is fairly concentrated, with large players operating in the market. The top ten competitors in the market made up 30.6% of the total market in 2023.
Preclinical CRO Global Market Opportunities And Strategies To 2033 from The Business Research Company provides the strategists; marketers and senior management with the critical information they need to assess the global preclinical CRO market as it emerges from the COVID-19 shut down.
Reasons to Purchase
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Understand how the market is being affected by the coronavirus and how it is likely to emerge and grow as the impact of the virus abates.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market research findings.
- Benchmark performance against key competitors.
- Utilize the relationships between key data sets for superior strategizing.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis.
Where is the largest and fastest-growing market for preclinical CRO? How does the market relate to the overall economy; demography and other similar markets? What forces will shape the market going forward? The preclinical CRO market global report from The Business Research Company answers all these questions and many more.
The report covers market characteristics; size and growth; segmentation; regional and country breakdowns; competitive landscape; market shares; trends and strategies for this market. It traces the market's history and forecasts market growth by geography. It places the market within the context of the wider preclinical CRO market; and compares it with other markets.
The report covers the following chapters
- Introduction and Market Characteristics- Brief introduction to the segmentations covered in the market, definitions and explanations about the segment by service, by type, by animal model, by model system and by end user.
- Key Trends- Highlights the major trends shaping the global market. This section also highlights likely future developments in the market.
- Macro-Economic Scenario- The report provides an analysis of the impact of the COVID-19 pandemic, impact of the Russia-Ukraine war and impact of rising inflation on global and regional markets, providing strategic insights for businesses in the preclinical CRO market.
- Global Market Size And Growth- Global historic (2018-2023) and forecast (2023-2028, 2033F) market values and drivers and restraints that support and control the growth of the market in the historic and forecast periods.
- Regional And Country Analysis- Historic (2018-2023) and forecast (2023-2028, 2033F) market values and growth and market share comparison by region and country.
- Market Segmentation- Contains the market values (2018-2023) (2023-2028, 2033F) and analysis for each segment by service, by type, by animal model, by model system and by end user in the market. Historic (2018-2023) and forecast (2023-2028) and (2028-2033) market values and growth and market share comparison by region market.
- Regional Market Size and Growth- Regional market size (2023), historic (2018-2023) and forecast (2023-2028, 2033F) market values and growth and market share comparison of countries within the region. This report includes information on all the regions Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa and major countries within each region.
- Competitive Landscape- Details on the competitive landscape of the market, estimated market shares and company profiles of the leading players.
- Competitive Benchmarking- Briefs on the financials comparison between major players in the market.
- Competitive Dashboard- Briefs on competitive dashboard of major players.
- Key Mergers and Acquisitions- Information on recent mergers and acquisitions in the market is covered in the report. This section gives key financial details of mergers and acquisitions which have shaped the market in recent years.
- Market Opportunities And Strategies- Describes market opportunities and strategies based on findings of the research, with information on growth opportunities across countries, segments and strategies to be followed in those markets.
- Conclusions And Recommendations- This section includes recommendations for preclinical CRO providers in terms of product/service offerings geographic expansion, marketing strategies and target groups.
- Appendix- This section includes details on the NAICS codes covered, abbreviations and currencies codes used in this report.
Markets Covered:
- 1) By Service: Bioanalysis And DMPK Studies; Toxicology Testing; Compound Management; Chemistry; Safety Pharmacology; Others Services
- 2) By Type: Patient-Derived Organoid (PDO) Model; Patient Derived Xenograft Model
- 3) By Animal Model: Small Animal Model; Large Animal Model
- 4) By Model System: In Vivo; In Vitro
- 5) By End User: Biopharmaceutical Companies; Government And Academic Institutes; Medical Device Companies; Other End-Users
- Companies Mentioned: Charles River Laboratories International, Inc.; Thermo Fisher Scientific Inc. (Pharmaceutical Product Development (PPD); Eurofins Scientific SE; Laboratory Corporation of America Holdings (Covance Inc.); ICON Plc.
- Countries: China; Australia; India; Indonesia; Japan; South Korea; USA; Canada; Brazil; France; Germany; Italy; Spain; UK; Russia
- Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
- Time-series: Five years historic and ten years forecast.
- Data: Ratios of market size and growth to related markets; GDP proportions; expenditure per capita; preclinical CRO indicators comparison
- Data segmentations: country and regional historic and forecast data; market share of competitors; market segments.
- Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.